GB0208609D0 - Compositions - Google Patents

Compositions

Info

Publication number
GB0208609D0
GB0208609D0 GBGB0208609.8A GB0208609A GB0208609D0 GB 0208609 D0 GB0208609 D0 GB 0208609D0 GB 0208609 A GB0208609 A GB 0208609A GB 0208609 D0 GB0208609 D0 GB 0208609D0
Authority
GB
United Kingdom
Prior art keywords
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0208609.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0208609.8A priority Critical patent/GB0208609D0/en
Publication of GB0208609D0 publication Critical patent/GB0208609D0/en
Priority to PCT/GB2003/001595 priority patent/WO2003088944A1/en
Priority to RU2004130438/15A priority patent/RU2004130438A/ru
Priority to MXPA04010082A priority patent/MXPA04010082A/es
Priority to BR0309115-5A priority patent/BR0309115A/pt
Priority to EP03720702A priority patent/EP1509199A1/en
Priority to AU2003224278A priority patent/AU2003224278A1/en
Priority to JP2003585696A priority patent/JP2005529874A/ja
Priority to PL03373293A priority patent/PL373293A1/xx
Priority to CNB038134608A priority patent/CN100362986C/zh
Priority to CA002482249A priority patent/CA2482249A1/en
Priority to KR10-2004-7016301A priority patent/KR20040097348A/ko
Priority to US10/510,968 priority patent/US20050232998A1/en
Priority to ARP030101279A priority patent/AR039408A1/es
Priority to TW092108404A priority patent/TW200407174A/zh
Priority to IL16442104A priority patent/IL164421A0/xx
Priority to IS7501A priority patent/IS7501A/is
Priority to ZA200408247A priority patent/ZA200408247B/xx
Priority to NO20044496A priority patent/NO20044496L/no
Priority to US11/934,983 priority patent/US20080060645A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0208609.8A 2002-04-13 2002-04-13 Compositions Ceased GB0208609D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0208609.8A GB0208609D0 (en) 2002-04-13 2002-04-13 Compositions
US10/510,968 US20050232998A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
PL03373293A PL373293A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
CA002482249A CA2482249A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
MXPA04010082A MXPA04010082A (es) 2002-04-13 2003-04-10 Composicion inhalante de polvo seco.
BR0309115-5A BR0309115A (pt) 2002-04-13 2003-04-10 Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco
EP03720702A EP1509199A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
AU2003224278A AU2003224278A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
JP2003585696A JP2005529874A (ja) 2002-04-13 2003-04-10 乾燥粉末組成物
PCT/GB2003/001595 WO2003088944A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition
CNB038134608A CN100362986C (zh) 2002-04-13 2003-04-10 干粉吸入组合物
RU2004130438/15A RU2004130438A (ru) 2002-04-13 2003-04-10 Сухая порошковая композиция для ингаляции
KR10-2004-7016301A KR20040097348A (ko) 2002-04-13 2003-04-10 흡입용 건조 분말 조성물
TW092108404A TW200407174A (en) 2002-04-13 2003-04-11 Composition
ARP030101279A AR039408A1 (es) 2002-04-13 2003-04-11 Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento
IL16442104A IL164421A0 (en) 2002-04-13 2004-10-05 Dry powder inhalant composition
IS7501A IS7501A (is) 2002-04-13 2004-10-11 thurrdufts innöndunar samsetning
ZA200408247A ZA200408247B (en) 2002-04-13 2004-10-12 Dry powder inhalant composition
NO20044496A NO20044496L (no) 2002-04-13 2004-10-21 Torr pulver innhaleringssammensetning
US11/934,983 US20080060645A1 (en) 2002-04-13 2007-11-05 Dry Powder Inhalant Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0208609.8A GB0208609D0 (en) 2002-04-13 2002-04-13 Compositions

Publications (1)

Publication Number Publication Date
GB0208609D0 true GB0208609D0 (en) 2002-05-22

Family

ID=9934856

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0208609.8A Ceased GB0208609D0 (en) 2002-04-13 2002-04-13 Compositions

Country Status (19)

Country Link
US (2) US20050232998A1 (https=)
EP (1) EP1509199A1 (https=)
JP (1) JP2005529874A (https=)
KR (1) KR20040097348A (https=)
CN (1) CN100362986C (https=)
AR (1) AR039408A1 (https=)
AU (1) AU2003224278A1 (https=)
BR (1) BR0309115A (https=)
CA (1) CA2482249A1 (https=)
GB (1) GB0208609D0 (https=)
IL (1) IL164421A0 (https=)
IS (1) IS7501A (https=)
MX (1) MXPA04010082A (https=)
NO (1) NO20044496L (https=)
PL (1) PL373293A1 (https=)
RU (1) RU2004130438A (https=)
TW (1) TW200407174A (https=)
WO (1) WO2003088944A1 (https=)
ZA (1) ZA200408247B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
JP2009513531A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
WO2006086270A1 (en) 2005-02-10 2006-08-17 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
WO2009031011A2 (en) * 2007-09-05 2009-03-12 Pfizer Limited Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine
TR201007251A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Kalsiyum kanal blokörü formülasyonu.
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
EP2819645A2 (en) * 2012-02-28 2015-01-07 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
AU2013259872B2 (en) 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2874928B1 (en) 2012-07-19 2016-06-15 Adamis Pharmaceuticals Corporation Powder feeding apparatus
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2991625A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
ES2942297T3 (es) * 2014-07-31 2023-05-31 Vectura Inc Formulaciones de polvo seco para inhalación
WO2016052897A1 (en) * 2014-09-30 2016-04-07 Hanmi Pharm. Co., Ltd. Dry powder for inhalation formulation having improved stability of combined active ingredients
KR20160117069A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입용 캡슐제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
DE3682457D1 (de) * 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
DK0994887T3 (da) * 1997-07-03 2003-03-17 Elan Drug Delivery Ltd Modificerede glycosider, præparater omfattet deraf og fremgangsmåder til anvendelse deraf
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
AU3664102A (en) * 2000-12-01 2002-06-11 Battelle Memorial Institute Method for stabilizing biomolecules in liquid formulations
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
EP1507754A1 (en) * 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists

Also Published As

Publication number Publication date
JP2005529874A (ja) 2005-10-06
US20080060645A1 (en) 2008-03-13
AU2003224278A1 (en) 2003-11-03
NO20044496L (no) 2004-11-15
ZA200408247B (en) 2006-03-29
CN1658837A (zh) 2005-08-24
AR039408A1 (es) 2005-02-16
EP1509199A1 (en) 2005-03-02
RU2004130438A (ru) 2005-06-10
CA2482249A1 (en) 2003-10-30
US20050232998A1 (en) 2005-10-20
TW200407174A (en) 2004-05-16
MXPA04010082A (es) 2004-12-13
BR0309115A (pt) 2005-02-01
CN100362986C (zh) 2008-01-23
KR20040097348A (ko) 2004-11-17
PL373293A1 (en) 2005-08-22
WO2003088944A1 (en) 2003-10-30
IS7501A (is) 2004-10-11
IL164421A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
GB0212062D0 (en) Jetable compositions
IL165372A0 (en) Immunodenic compositions
GB0224415D0 (en) Compositions
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
GB0318894D0 (en) Composition
GB0208609D0 (en) Compositions
GB0203421D0 (en) Composition
GB0227244D0 (en) Composition
GB0208608D0 (en) Composition
GB0221894D0 (en) Compositions
GB0203280D0 (en) Anti-glycolytic composition
AU2003269904A8 (en) Antigen-polymer compositions
GB0203395D0 (en) Compositions
GB0203396D0 (en) Compositions
GB0211924D0 (en) Composition
GB0229808D0 (en) Novel compositions
GB0318152D0 (en) Composition
GB0218241D0 (en) Composition
GB0217366D0 (en) Compositions
EP1495751A4 (en) hair dye
GB2394114B (en) Compositions
AU2003216382A8 (en) Idothyronine compositions
GB0228540D0 (en) Novel compositions
GB0213767D0 (en) Composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)